Search

May 12, 2017—The 2017 Expert Consensus Statement on Catheter and Surgical Ablation of Atrial Fibrillation represents a complete rewrite of the 2012 HRS/EHRA/ECAS Expert Consensus Statement. This document provides updated definitions, mechanisms, and rationale for atrial fibrillation (AF) ablation and consensus recommendations concerning indications, strategies, techniques, and endpoints, technology and tools, and follow-up considerations for AF ablation. The document also provides definitions to be used in clinical trials and recommendations that will impact clinical trial design. The document was developed in joint partnership with EHRA, ECAS, APHRS, and SOLAECE. Collaborators on the document include STS, ACC, AHA, CHRS, JHRS, and SOBRAC. 

This document features a clinician summary  (an educational derivative product of the full document), a slide set  (an educational tool for electrophysiologists, cardiologists, and other licensed health care practitioners), an Executive Summary,  and an interview with Hugh Calkins, MD, FHRS, by HeartRhythm Online Editor Daniel P. Morin, MD, MPH, FHRS. 

The Catheter and Surgical Ablation of Atrial Fibrillation pocket card, a valuable educational reference tool created in partnership with Guideline Central, is available across multiple platforms, including print, electronic media, and the Guideline Central mobile app. Visit www.guidelinecentral.com  to access the pocket card.

September 18, 2016—Drug therapy with beta-blockers represents the therapeutic mainstay for both LQTS and CPVT. The goal of the document is to help clinicians understand the importance of beta-blocker therapy in these two genetic disorders, as well as to provide clinical guidance on the choice of agents. Nadolol, when available, has been the preferred beta-blocker utilized by the largest LQTS/CPVT specialty centers throughout the world for the past 25 years.

June 10, 2016—Ventricular cardiomyopathies have been well classified; however, a definition and detailed analysis of atrial cardiomyopathy are lacking from the literature. The purpose of the present consensus report was to define atrial cardiomyopathy, to review the relevant literature, and to consider the impact of atrial cardiomyopathies on arrhythmia management and stroke.

This document has been retired and replaced by "2017 HRS/EHRA/ECAS/APHRS/SOLAECE Expert Consensus Statement on Catheter and Surgical Ablation of Atrial Fibrillation."

March 5, 2012—The purpose of the 2012 Consensus Statement is to provide a state-of-the-art review of the field of catheter and surgical ablation of atrial fibrillation. It reports on the findings of a Task Force, convened by the Heart Rhythm Society (HRS), the European Heart Rhythm Association (EHRA), and the European Cardiac Arrhythmia Society (ECAS) and charged with defining the indications, techniques, and outcomes of this procedure.

This document has been retired and replaced by "2014 AHA/ACC/HRS Guideline for the Management of Patients with Atrial Fibrillation."

February 14, 2011—This guideline update states that dabigatran, a new antithrombotic agent that was recently approved by the U.S. Food and Drug Administration, is an alternative to warfarin to help prevent dangerous blood clots in patients with atrial fibrillation. The update is a joint publication of the American College of Cardiology Foundation (ACCF), the American Heart Association (AHA), and the Heart Rhythm Society (HRS). 

This document has been retired and replaced by "2014 AHA/ACC/HRS Guideline for the Management of Patients with Atrial Fibrillation."

December 20, 2010—This guideline update is based on a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines.

May 7, 2014—This expert consensus statement was written by experts and developed in collaboration with and endorsed by the American College of Cardiology Foundation (ACCF), the American Heart Association (AHA), and the Pediatric and Congenital Electrophysiology Society (PACES).  Endorsed by Asia Pacific Heart Rhythm Society (APHRS), European Heart Rhythm Association (EHRA), and Sociedad Latinoamericana de Estimulacion Cardiaca y Electrofisiologia (SOLAECE)-Latin American Society of Cardiac Pacing and Electrophysiology.

May 8, 2017—Ambulatory ECG (AECG) is commonly used in a variety of clinical contexts to detect cardiac arrhythmias and/or arrhythmia patterns that are not readily obtained from the standard ECG. Accurate and timely characterization of arrhythmias is crucial to direct therapies that can have an important impact on diagnosis, prognosis, or patient symptom status. The rhythm information derived from the large variety of AECG recording systems can often lead to appropriate and patient-specific medical and interventional management. This document provides background and framework from which to apply AECG techniques in clinical practice, as well as clinical research.

Download the Russian translation here

The Heart Rhythm Society endorsed the document on January 8, 2018.

March 16, 2018—This expert consensus statement provides recommendations for designing scientific studies, reports, and registries relating to lead extraction. The recommendations are directed to all scientists and health care professionals and are pertinent to clinical trials, registries, guidelines, quality assurance, and educational programs. The document also lists numerous gaps in evidence related to lead extraction, with the purpose to trigger joint collaboration in scientific trials and registries.

The Heart Rhythm Society endorsed the document on October 5, 2017. 

March 20, 2018—This position statement summarizes knowledge and provides recommendations on diagnosis and treatment of arrhythmias in patients with congenital heart defects (CHD), because, in many cases, the anatomy and management of arrhythmias in adult patients cannot directly be applied to patients with CHD. This document mainly addresses arrhythmias in adult CHD.